BioSilta Introduces EnPresso B Growth Systems for Bacterial Cultures
BioSilta Oy, a developer of advanced microbial growth systems, has announced the commercial launch of the first products in its proprietary EnPresso B range of reagent-based growth systems for bacterial cultures. Extensive results from independent labs around the world (available at www.biosilta.com) have confirmed that these new products typically increase protein yields by five to 100-fold and improve protein functionality when compared with results using conventional growth media.
The EnPresso B range has been developed in response to findings from market research involving more than 1200 scientists routinely growing bacterial cultures for the expression of recombinant proteins at laboratory scale. The majority of respondees highlighted insufficient yield, followed by quality problems such as poor protein solubility or low activity, as their main challenges.
The products are EnPresso B, EnPresso B Animal-free (supplied with documentation to certify that the product is free from animal-derived components), and EnPresso B Defined Nitrogen-free, used to significantly increase the yield of 15N-labeled proteins for NMR analysis.
For ease of use the products are supplied as presterilized tablets, which are simply added to sterile, filtered water. Optimized protocols enable researchers to go from pre-culture to harvest within 2 days, using standard lab equipment such as shake flasks or 24 deep well plates.
The EnPresso B range incorporates the Company’s patented EnBase technology that offers a novel approach to control the feeding, and thereby growth rate, of microbial cultures. A glucose-releasing agent breaks down long chains of polysaccharides, releasing glucose units to feed the microbes. As well as glucose, EnPresso tablets provide other key elements to support growth and control pH. Cells grow steadily to reach higher densities before induction of protein expression and continue in linear growth for many hours after induction. Proteins are expressed under optimal metabolic conditions thereby reducing the risk of incorrect folding and increasing the percentage of soluble protein. In contrast, microbes cultivated in conventional media grow in an uncontrolled manner, consuming nutrients, changing pH and depleting oxygen. Growth stops within hours, limiting protein yields and ‘too fast’ metabolism produces poor quality proteins.
Bob Penney, CEO, BioSilta Oy, said: “In our market research more than 70% of scientists confirmed that their main challenge when producing recombinant proteins in bacterial systems was insufficient yield, followed by problems with poor solubility and functionality. We firmly believe that EnPresso B growth systems very significantly address these issues and will revolutionize the role of bacterial cell culture in protein expression. Scientists will spend less time optimizing expression systems and more time focused on their true research objectives.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance